Clinical Trial Update: Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating vorasidenib for Asian participants with residual or recurrent grade 2 IDH-mutant glioma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idh-mutant Glioma
• Low-grade Glioma

Drugs mentioned

• Vorasidenib (vorasidenib)

Snippet

Sponsor: Servier | Conditions: Residual or Recurrent Grade 2 IDH Mutant Glioma | Phase 3 | Status: ACTIVE_NOT_RECRUITING